The global pulmonary drug delivery devices/systems market size was estimated at USD 36.5 billion in 2016 and is expected to grow at a CAGR of 4.7% over the forecast period. Increasing incidence of chronic respiratory diseases is expected to accelerate the demand for Pulmonary Drug Delivery Systems (PDDS) in the near future.
As per the data published by the Global Asthma Network (GAN) in “The Global Asthma Report 2014”, asthma affects nearly 334 million people worldwide. The substantial increase in prevalence and incidence of respiratory diseases has led to an increase in the patient population, which has in turn increased the demand for these systems. This consequent increase in demand is estimated to drive growth over the coming years.
In addition, technological advancements are anticipated to provide the market with lucrative opportunities. Limitations of traditional treatments, such as the late onset of action and low efficacy, are projected to encourage the development of novel targeted drug delivery devices, thereby boosting growth during the future period.
Moreover, the rise in the number of initiatives undertaken by government and non-government organizations is increasing the overall revenue. For instance, CDC’s National Asthma Control Program (NACP) provides funds for educating asthma affected patients. Such initiatives are likely to increase awareness about asthma, which will increase the adoption of PDDS in the treatment of Chronic Obstructive Pulmonary Disease (COPD) and asthma, leading to industry growth.
Metered Dose Inhalers (MDI) segment held the largest share of 66.7% of the market in 2016. The presence of global key players involved in the development of novel MDIs and the high acceptance rate of these devices in developing regions, such as Asia Pacific and Latin America, are some of the factors responsible for the revenue generated by this segment.
Dry Powder Inhaler (DPI) segment is anticipated to grow at a lucrative rate during the future period. Advantages such as cost-effectiveness, short administration, and preparation time, and others are anticipated to increase the use of these inhalers by end users. Due to technological advancements, DPI emerged as a preferred medical device for the treatment of a diverse range of respiratory disorders, which has in turn increased the utilization of these products. The abovementioned factors are likely to propel the growth of this segment.
Nebulizers are projected to grow at a steady rate over the future period. These devices are the most frequently used inhalation devices in hospitals. Nebulizers have a high adoption rate in home care and emergency medicine due to their benefits, such as greater comfort, administration of large dosage, and favorable reimbursement scenario, which is expected to help maintain a steady demand for this product segment.
The accessories segment is estimated to grow at a CAGR of 5.6% owing to the launch of new products and extensive R&D in this field. These products are necessary for efficient drug delivery to a patient’s lungs. Abovementioned factors are anticipated to support the segment development
The asthma segment held the dominant share in 2016. An effective inhalation therapy that uses DPIs and MDIs is considered to be the basis of asthma management. Owing to the high number of people affected by asthma, the demand, and usage of devices such as MDIs and DPIs for asthma management are increasing, boosting the growth of this application.
The dynamic growth of the COPD segment can be attributed to the high incidence and mortality of this disease. Favorable reimbursement policies for the treatment of COPD and a rise in the number of government and non-government organizations that provide COPD treatment are increasing revenue generated by this segment. Owing to these factors, the COPD segment is expected to grow consistently.
Treatment of allergic rhinitis involves the use of nasal sprays, dry powder inhalers, and allergy shots. According to the National Center for Health Statistics (NCHS), in 2016, 20 million adults aged more than 18 years and 6.1 million children in the U.S. were diagnosed with allergic rhinitis. Due to a large patient pool, the demand for PDDS devices is projected to increase, resulting in the development of this segment.
The other application segment is anticipated to exhibit progress owing to the rise in patients diagnosed with various chronic diseases. According to the CDC, in 2016, 29.4 million adults were diagnosed with sinusitis in the U.S. Treatment of such diseases demands the use of PDDS. These factors are expected to provide this segment growth opportunity.
Hospital pharmacies segment held the dominant share of the PDDS in 2016 and is projected to continue its dominance in the future. Hospitals provide extensive treatments, care, quick reimbursements, and insurance policies owing to which patients prefer hospital pharmacies. Furthermore, an increased number of hospitalizations is expected to boost the growth of this segment.
Retail pharmacies are expected to show steady growth over the future period, owing to easy accessibility and affordability. Hospitals and clinics rely on retail pharmacies as a backup for medications. Moreover, most of the home care products are available in retail pharmacies. These factors are likely to be responsible for the constant growth of this segment.
E-commerce is anticipated to grow at a CAGR of 5.4% during the forecast period. Various factors such as improving healthcare infrastructure in developing regions and convenience of purchasing in comparison to retail or hospital pharmacies have supported the growth of this distribution channel to a great extent.
The trend of online purchasing and the demand for it is growing due to comfort, flexibility, and convenience, which is increasing the revenue generated by this segment. Moreover, online shopping offers discounts that benefit customers. These factors are expected to collectively boost the demand for online pharmacies.
As of 2016, hospitals accounted for the largest revenue share of the PDDS. Hospitals are currently advancing in terms of technology usage. Technologically advanced medical devices are being extensively used in hospitals to improve point-of-care. Furthermore, hospitals also provide a wide array of treatments for various respiratory diseases.
In developed regions such as North America and Europe, hospitals also provide quick reimbursements for COPD treatment under the Medicare program. These facts are expected to stimulate the utilization of PDDS devices in hospital settings, leading to growth.
The home care segment is expected to exhibit lucrative growth over the future period. Growing preference for home healthcare is expected to boost the use of PDDS devices in home care settings. An increase in the cost of health care services and a shortage of healthcare facilities have also led to an increase in demand for home care services.
The introduction of technologically advanced devices, which are portable and small-sized, has resulted in patients using such products at home. These devices are convenient, easy-to-use, and do not require any special training to operate. These associated advantages are expected to increase the adoption of PDDS in home care, thereby boosting the growth of this segment.
North America held the dominant share of PDDS and was valued at USD 14.9 billion in 2016. This growth can be attributed to the rising incidence of diseases such as COPD and asthma. A rise in the number of patients affected by these diseases, increases the demand for diagnostic devices, such as PDDS, thereby boosting the growth of this region.
In addition, the local presence of key pharmaceutical and medical devices players, advanced healthcare infrastructure, aging population, high disposable income, and lifestyle changes are factors contributing to the overall growth of the North America respiratory drug delivery devices market.
Asia Pacific region is anticipated to grow at an exponential rate of 6.2% due to the high prevalence of COPD, which indicates a substantial socioeconomic burden in this region. Continuous increase in the number of asthmatic and allergic rhinitis patients is also a major factor that is anticipated to propel the market demand for PDDS in the Asia Pacific region during the forecast period.
Furthermore, a rise in the number of supportive nongovernment organizations, such as the Asia Pacific Association of Allergy, Asthma and Clinical Immunology (APAAACI), is estimated to increase awareness about the treatment of respiratory disorders amongst patients, leading to market growth. Continuous increase in R&D activities by key market players to develop novel respiratory devices is also expected to support the growth of the Asia Pacific region.
Pulmonary drug delivery devices market is progressing owing to the increasing demand for better treatment options, efficient drug delivery, and rapid treatment of local respiratory disorders. This has attracted several local and international medical device manufacturers to invest in the market.
Some of the key players in this market are GlaxoSmithKline plc, Philips Respironics, Boehringer Ingelheim GmbH, Novartis AG, 3M Healthcare, GF Health Products, Inc., Merck & Co., Inc., and AstraZeneca. The competitive milieu has led to improved drug delivery, minimum dosage requirement, and increased patient safety.
The industry is competitive in nature with key players involved in mergers & acquisitions, new product development, collaborations & partnerships, and expansion strategies to augment market penetration. For instance, in May 2017, Koninklijke Philips N.V. entered into a definitive agreement to acquire Respiratory Technologies, Inc. (RespirTech) with an aim to expand its respiratory care product portfolio.
Rise in the number of industry participants is expected to increase the competition in the near future. Owing to this fact, competitive rivalry in the respiratory market is expected to be high over the forecast period.
Major players of pulmonary drug delivery systems market such as CareFusion Corporation, Novartis AG, GlaxoSmithKline, Sunovion Pharmaceuticals Inc., Boehringer Ingelheim, Merck & Co., Allied Healthcare Products, Inc., 3M Health Care, PARI Respiratory Equipment, Inc., Omron Healthcare, Inc., Philips Respironics, Inc., and GF Health Products Inc. These companies focus on unmet market needs, targeting regions, development of innovative products, and mergers & acquisitions in order to expand their market share. Additionally, these players provide services that are aimed at improving the quality of drug delivery systems and better patient care. Moreover, the need for more efficient systems and competition among new market entrants are anticipated to provide a growth platform to the market over the forecast period.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2017 - 2025
Revenue in USD Million and CAGR from 2017 to 2025
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Revenue forecast, company share, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global pulmonary drug delivery systems market on the basis of product, application, distribution channel, end use, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Metered Dose Inhalers
Dry Powder Inhalers
Application Outlook (Revenue, USD Million, 2014 - 2025)
Distribution Channel Outlook (Revenue, USD Million, 2014 - 2025)
End-use Outlook (Revenue, USD Million, 2014 - 2025)
Hospitals & Clinics
Regional Outlook (Revenue, USD Million, 2014 - 2025)
The Middle East and Africa
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
Leading SME award by D&B
"The quality of research they have done for us has been excellent."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.